Industry News

The following is an excerpt from a statement from Genentech. Read the entire statement 聽HERE.


Genentech has recently learned that a patient in the Phase III HAVEN 2 clinical trial developed a neutralizing anti-drug聽antibody.

For聽this patient, the anti-drug antibody resulted in reduced efficacy of HEMLIBRA.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.